Introduction
============

Malignant obesity hypoventilation syndrome (MOHS) refers to the association between morbid obesity (body mass index \>40 kg/m^2^), daytime hypercapnia (PCO~2~\>45 mmHg) after other respiratory or neuromuscular causes of alveolar hypoventilation have been excluded, and multiple organ disorders (diabetes mellitus, arterial hypertension, metabolic syndrome, obstructive sleep apnea syndrome) \[[@B1]\]. Acute respiratory failure (ARF) is a common life-threatening complication of MHOS. Non-invasive ventilation (NIV) provides the cornerstone of the therapeutic management of decompensated MOHS \[[@B2]\]. We aimed to identify the determinants of NIV success or failure in this indication.

Methods
=======

A monocentric prospective observational study including 48 patients with MOHS and treated by NIV for ARF over a 2-year period.

Results
=======

NIV failed to reverse ARF in only seven patients. NIV failure was associated with a sixfold increase in in-hospital mortality (85.7% vs. 14.6%; *P \<*0.001). Factors associated with NIV failure and need for endotracheal intubation included pneumonia (*n =*5, 71.4% vs. *n =*8, 19.5%; *P*= 0.01), higher SOFA (11 vs. 5; *P \<*0.001) and SAPS 2 (69 vs. 39; *P*= 0.001) score at admission. The only factor associated with successful response to NIV was idiopathic decompensated MOHS (*n =*19, 100% vs. *n =*0, 0%; *P*= 0.03). In these patients, pH (7.23 vs. 7.28 vs. 7.44, respectively, at H0, H2, H24; *P \<*0.05) and PCO~2~(74.5 vs. 68.5 vs. 57 mmHg, respectively, at H0, H2, H24; *P \<*0.05) dramatically improved with NIV.

Conclusion
==========

NIV provides a very efficient therapy to reverse hypercapnic ARF in morbidly obese patients. Multiple organ failure and pneumonia are the main factors associated with NIV failure in patients with MOHS.
